Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer

Crit Rev Oncol Hematol. 1999 Nov;32(2):105-12. doi: 10.1016/s1040-8428(99)00025-6.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Antiemetics / economics*
  • Antiemetics / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Canada
  • Cost-Benefit Analysis
  • Humans
  • Metoclopramide / economics*
  • Metoclopramide / therapeutic use
  • Middle Aged
  • Nausea / chemically induced
  • Nausea / prevention & control
  • Ondansetron / economics*
  • Ondansetron / therapeutic use
  • Quality of Life
  • Vomiting / chemically induced
  • Vomiting / prevention & control

Substances

  • Antiemetics
  • Antineoplastic Agents
  • Ondansetron
  • Metoclopramide